Topics

Gilead Sciences Announces First Quarter 2019 Financial Results

16:01 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
- Product Sales of $5.2 billion -- Diluted EPS of $1.54 per share -- Non-GAAP Diluted EPS of $1.76 per share -- Reiterates Full Year 2019 Guidance - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results ...

Other Sources for this Article

Investors
Robin Washington
(650) 522-5688

Sung Lee
(650) 524-7792

Media
Amy Flood
(650) 522-5643

NEXT ARTICLE

More From BioPortfolio on "Gilead Sciences Announces First Quarter 2019 Financial Results"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...